Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Exscientia Ltd.
Industry experts at BioFuture 2022 highlighted the growing importance of digital technology in drug discovery and development, and also the limitations remaining.
Having led $30bn of acquisitions of companies at Sanofi, the new challenge for its former global head of partnering is to help make Owkin, “the most disruptive AI biotech company in the world,” he tells Scrip.
Deal Snapshot: The companies first partnered in January 2019, with a focus on more than 20 diseases. The renewed deal will support development of additional disease models using artificial intelligence and machine learning.
Accenture released its Life Sciences Technology Vision 2022 report, including a survey of biopharma execs on trends like synthetic data and quantum computing.
- Artificial Intelligence
- Drug Discovery Technologies
- Other Names / Subsidiaries
- Allcyte GmbH